The European Medicines Agency (EMA) has recommended the approval of Novavax’s corona vaccine. That could be a decisive step in convincing more people of the corona vaccination.
The EU Medicines Agency (EMA) has cleared the way for the approval of the corona vaccine from the US manufacturer Novavax. The EMA announced on Monday in Amsterdam. After approval by the EU Commission, this will be the fifth corona vaccine in the EU.
The responsible commission of experts issued the recommendation after an extraordinary meeting. The experts had already evaluated studies on the effects and risks in the long-running test procedure.
EU criteria for corona vaccine met
After a detailed assessment, the responsible committee came to the conclusion that “the EU criteria for effectiveness, safety and quality are met,” said the EMA. Now the EU Commission still has to agree. But that is a matter of form.
The Novavax vaccine (Nuvaxovid) is given in two doses about three weeks apart. According to the studies, it is highly effective with an infection protection of around 90 percent. How strong it works with the very contagious Omicron variant, however, is unclear. So far there have only been cases of mild side effects.
Novavax is based on different technology
The preparation could be an alternative for vaccine skeptics because it is based on a different technology. Unvaccinated people who have doubts about the rest of the vaccines could potentially be changed their minds.
The Novavax preparation is not an mRNA vaccine like the preparations from Biontech and Moderna, nor a vector vaccine like those from Astrazeneca and Johnson & Johnson. It contains tiny particles made up of a laboratory-made version of the Sars-CoV-2 spike protein. They are supposed to ensure that the body itself stimulates the production of antibodies and T cells against the virus.
Further source:.
Source From: Stern
